AC Immune SA announced positive interim safety and tolerability data from the ABATE Phase 1b/2 trial of ACI-24.060 in individuals living with Down syndrome. ACI-24.060 is an active immunotherapy designed to target toxic forms of amyloid beta.
The interim analysis, based on data from the first two cohorts receiving low-dose and mid-dose ACI-24.060 for up to one year, showed no serious adverse events related to the study drug. Crucially, no cases of amyloid-related imaging abnormalities (ARIA) were observed in this patient population.
Based on these encouraging findings, AC Immune plans to open the high-dose cohort in the ABATE trial for individuals with Down syndrome. ACI-24.060 has previously received Fast Track designation from the U.S. FDA for the treatment of Alzheimer's disease, underscoring its therapeutic potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.